Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national registerFrançois Prince, Lisette W. A. van Suijlekom‐Smit, Marinka Twilt et al.|Annals of the Rheumatic Diseases|2008Cited by 220
Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic ArthritisM.H. Otten, Lisette W. A. van Suijlekom‐Smit, Femke H. M. Prince et al.|JAMA|2011Cited by 149
MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritisJanneke Anink, Dirk Holzinger, Lisette W. A. van Suijlekom‐Smit et al.|Arthritis Research & Therapy|2015Cited by 81
Tumor Necrosis Factor-blocking Agents for Children with Enthesitis-related Arthritis — Data from the Dutch Arthritis and Biologicals in Children Register, 1999–2010M.H. Otten, Lisette W. A. van Suijlekom‐Smit, Koert M. Dolman et al.|The Journal of Rheumatology|2011Cited by 73
Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritisFrançois Prince, Lisette W. A. van Suijlekom‐Smit, Lianne M. Geerdink et al.|Annals of the Rheumatic Diseases|2009Cited by 64